Drug Trial Radar · NCT01438489
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Oct 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
626
Actual
Start
Jan 2012
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of MEDI-546 compared to placebo in subjects with chronic, moderately-to-severely active systemic lupus erythematosus (SLE) with an inadequate response to standard of care treatment for SLE.
Conditions
- Systemic Lupus Erythematosus
Interventions
Anifrolumab 300 mgBiological
Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
Anifrolumab 1000 mgBiological
Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
PlaceboOther
Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169Time frame: Day 169
- Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169Time frame: Day 169
Locations
79 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
La Jolla, California
Research Site
La Palma, California
Research Site
Long Beach, California
Research Site
Los Angeles, California
Research Site
Palm Desert, California
Research Site
San Leandro, California
Research Site
Upland, California
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Orlando, Florida
Research Site
Palm Harbor, Florida
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Decatur, Georgia
Research Site
Stockbridge, Georgia
Research Site
Idaho Falls, Idaho
Research Site
Chicago, Illinois
Research Site
Indianapolis, Indiana
Research Site
Las Cruces, New Mexico
Research Site
New York, New York
Research Site
Charlotte, North Carolina
Research Site
Raleigh, North Carolina
Research Site
Columbus, Ohio
Research Site
Edmond, Oklahoma
Research Site
Tulsa, Oklahoma
Research Site
Memphis, Tennessee
Research Site
Houston, Texas
Research Site
Seattle, Washington
Research Site
Spokane, Washington
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Barranquilla, Colombia
Research Site
Bogotá, Colombia
Research Site
Bucaramanga, Colombia
Research Site
Chía, Colombia
Research Site
Medellín, Colombia
Research Site
Brno, Czechia
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.